|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Products | |||||
| Services | |||||
| Total revenue | |||||
| Cost of sales | |||||
| Products | |||||
| Services | |||||
| Total cost of sales | |||||
| Gross loss | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Sales and marketing | |||||
| General and administrative | |||||
| Impairment of goodwill and intangible assets | |||||
| Impairment of long-lived assets | |||||
| Restructuring and other costs | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expense), net: | |||||
| Change in fair value of warrant liabilities | |||||
| Impairment of investments and certain other assets | |||||
| Interest expense | |||||
| Interest income | |||||
| Gain on extinguishment of debt | |||||
| (Loss) gain from acquisition of EM4 | |||||
| Changes in fair value of derivative liability | |||||
| Losses and impairments related to investments and certain other assets, and other income (expense) | |||||
| Total other income (expense), net | |||||
| Loss before provision for income taxes | |||||
| Loss before reorganization items and provision for income taxes | |||||
| Reorganization items | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Net unrealized (losses) gains on available-for-sale debt securities | |||||
| Comprehensive loss | |||||
| Less: Deemed dividend on Series A preferred stock | |||||
| Net loss attributable to common stockholders | |||||
| Net loss per share attributable to common stockholders: | |||||
| Basic (in dollars per share) | |||||
| Diluted (in dollars per share) | |||||
| Shares used in computing net loss per share: | |||||
| Basic (in shares) | |||||
| Diluted (in shares) | |||||
Loading...